How Glioblastoma Clinical Trials Work - and Whether to Join

A glioblastoma clinical trial is a research study that tests a new treatment - a drug, device, combination, or immune approach - in people with the disease. Each trial has eligibility criteria and a limited timeframe for joining. Knowing how to find and enter a trial can help you access an option you might otherwise miss. About 8 to 11 percent of newly diagnosed glioblastoma patients enroll - mostly because the enrollment process is rarely explained at diagnosis.

What Is a Glioblastoma Clinical Trial?

A clinical trial is a structured human research study governed by a protocol - a detailed plan approved by an ethics board and a regulatory authority. The protocol defines who can join, what the treatment involves, how patients will be monitored, and what data will be collected.

Most trials compare an experimental arm against a control arm. The control arm is almost always current standard-of-care: for newly diagnosed GBM, that typically means the Stupp protocol - temozolomide chemotherapy combined with radiation. The experimental arm adds or substitutes something new. In a randomized trial, an algorithm assigns which arm you go into. Your oncologist does not choose.

Trials are run by academic medical centers, pharmaceutical companies, cooperative research groups, and advocacy organizations. All registered studies are searchable on ClinicalTrials.gov, the US federal registry that lists trials open worldwide, including sites in India, Europe, and the Middle East.

The Four Phases - What Each One Means for You

Every trial belongs to a phase. The phase tells you what question the trial is trying to answer - and how much evidence already exists about the experimental treatment.

• Phase I - Is it safe? Small groups of 20 to 40 patients test escalating doses to find the highest tolerable amount. You may be among the first people to receive the experimental agent. The primary goal is safety data, not a therapeutic promise.
• Phase II - Does it show activity? A larger group - often 50 to 150 patients - receives the dose identified in Phase I. Researchers look for signals of efficacy: tumor response, stable disease, or early survival trends. Results here determine whether a Phase III trial is warranted.
• Phase III - Is it better than current treatment? Large, randomized trials compare the experimental treatment directly against standard-of-care. These studies drive regulatory approvals. Enrollment can reach several hundred patients. Even if you are randomized to the control arm, you receive current standard treatment.
• Phase IV - What happens after approval? Post-approval monitoring in a broader population over time, tracking long-term safety and real-world effectiveness. Phase IV GBM trials are uncommon given the limited number of agents that have received approval for this disease.

For caregivers evaluating a trial, the phase is the first filter to apply. Phase I carries more uncertainty about benefit. Phase III means the experimental treatment has already shown enough early promise to justify comparison against the current standard in a large study.

Why Do So Few GBM Patients Enroll?

This is a known problem in neuro-oncology. A review of the glioblastoma trial landscape found only 8 to 11 percent of newly diagnosed patients ever enroll - a rate experts call dangerously low for a disease with survival rates this poor.

Two factors explain most of the gap. First, patients fail specific eligibility criteria - one institutional analysis found this accounts for roughly 46 percent of non-enrollments. Second, patients missed the enrollment window - they started treatment before learning about a trial, which accounted for about 27 percent of missed opportunities, according to an analysis of disparities in GBM trial enrollment.

The practical consequence is clear: ask about trials at your first neuro-oncology appointment, not after radiation has started. Many trials have narrow entry windows - sometimes only between surgical confirmation and the start of radiation, a gap of as little as two to three weeks. Waiting to ask about trials can close the door before you even know it exists.

Where to Search for Open GBM Trials

Several databases list active glioblastoma trials. Use multiple sources since not all trials appear in every registry.

• ClinicalTrials.gov - The official US federal registry. Search the condition "glioblastoma," then filter by recruiting status, age group, and country. Each listing shows the phase, full eligibility criteria, participating site locations, and a principal contact name. International trials appear here when registered.
• National Brain Tumor Society - The NBTS publishes regular roundups of newly opened brain tumor trials and maintains a guided trial-matching tool at braintumor.org, organized by tumor type and treatment history.
• American Brain Tumor Association - The ABTA's clinical trial resources provide plain-language guidance on what trial participation involves, alongside search tools built specifically for brain tumor patients.
• Your neuro-oncologist's institution - Academic centers often run their own trials that don't appear in public databases. Ask directly whether your hospital has open trials and whether it participates in networks like the Alliance or NRG Oncology.

If you are at recurrence and building the case for a next-line option, the guide to building your second opinion case after recurrence covers how to organize your clinical history so trial screening is faster and more targeted.

What Makes You Eligible - or Ineligible?

Eligibility criteria are not arbitrary gatekeeping. They exist so researchers can interpret results across a group of patients with similar enough profiles. A trial that mixes MGMT-methylated and unmethylated patients without separating the groups cannot tell you whether the drug worked because of - or despite - methylation status. Knowing the most common criteria helps you prepare for formal screening.

• Molecular markers - MGMT methylation status and IDH mutation status are required variables in many GBM trials. Some studies target only MGMT-methylated tumors; others are designed specifically for IDH-wildtype GBM. If your tumor has not yet been fully profiled, this alone can determine which trials are open to you. The article on immunotherapy trials and your molecular profile explains how specific markers open or close specific trial doors.
• Performance status - Most trials use the Karnofsky Performance Score (KPS) or the ECOG scale to assess how independently a patient is functioning day to day. Many Phase III trials require a KPS of 70 or above - roughly, able to care for oneself with some effort. Phase I trials sometimes accept lower scores because safety data is the primary goal.
• Prior treatment history - Patients who have already received bevacizumab are excluded from most antiangiogenic drug trials. The number of prior treatment lines matters in recurrence studies. A history of certain autoimmune conditions or organ transplants can trigger broad exclusions in immunotherapy trials.
• Organ function - Liver enzymes, kidney function, and blood counts are checked at screening. Elevated liver enzymes - common in patients on dexamethasone - can disqualify entry into trials testing hepatically metabolized drugs. Low platelet counts from prior temozolomide cycles can exclude patients from trials requiring dose-dense chemotherapy arms.
• Washout periods - Most trials require a gap - often four to six weeks - after the last dose of prior systemic therapy before enrollment. This gap separates the effects of the previous treatment from the experimental agent in the data. For patients who recently received bevacizumab, washout periods can extend to six to eight weeks.
• Tumor characteristics - Device and procedure-based trials often specify tumor size, depth, location, or recurrence pattern as eligibility conditions. Convection-enhanced delivery studies, focal radiation trials, and laser ablation studies are examples where tumor anatomy matters as much as blood markers.

What Questions Should You Ask Before Signing the Consent Form?

Informed consent is a process, not a single signature. You have the right to ask these questions - and to take time to consider the answers - before agreeing to participate:

1. What phase is this trial, and what is the central question it is designed to answer?
2. What side effects are already known or suspected from prior Phase I or preclinical data?
3. Is there a placebo or control arm, and if so, what treatment does the control group actually receive?
4. How many additional clinic visits, blood tests, or scans will this trial require beyond my current care schedule?
5. Can I continue my existing medications - anti-seizure drugs, steroids, and supportive supplements - while on the trial?
6. What are the stopping rules? Under what conditions would I be removed from the study?
7. If I withdraw from the trial voluntarily, will my access to standard-of-care be affected?
8. Are any travel costs, accommodation, or other out-of-pocket expenses covered by the trial sponsor?

To compare trials side-by-side or against other options, see the companion article on evaluating a glioblastoma clinical trial before you enroll, which covers the key decision points.

Trials for Newly Diagnosed vs Recurrent GBM

The trial landscape looks markedly different depending on where you are in the treatment timeline.

Newly diagnosed. Most Phase III trials for newly diagnosed GBM use the Stupp protocol and add or substitute an experimental treatment with standard temozolomide and radiation. The enrollment window is narrow - typically between surgery and the start of radiation, sometimes only two to three weeks. If your hospital doesn't run trials and you don't get a quick referral, this window closes before anyone even mentions trials.

Mid-treatment - maintenance phase. Some trials enroll patients who have completed chemoradiation and are entering the temozolomide maintenance phase. These add a second agent alongside maintenance chemotherapy. The window here is slightly wider but still defined by specific cycle timing relative to the end of radiation.

Recurrent GBM. Most trials target recurrence. Phase I and Phase II studies of new approaches - immunotherapies, oncolytic viruses, repurposed drugs, and CAR-T cells - happen mostly at this stage, when the risk-benefit calculation for experimental treatment shifts. More patients qualify for trials at recurrence than at initial diagnosis, and the range of trial types is larger.

International Patients and Cross-Border Trial Access

If you are based in the GCC, South Asia, Africa, or Southeast Asia, accessing clinical trials takes extra planning. ClinicalTrials.gov includes trials from many countries; filtering by location can identify participating sites in India, Singapore, Turkey, and parts of Europe. Some global multi-site trials specifically recruit across Asia and the Middle East.

When no trials are available in your home country, you need to decide whether traveling to an enrolling site makes sense - considering repeated travel over weeks or months, whether the sponsor covers costs, and whether you need to be at the same location for all monitoring visits. Some trials allow a local co-investigator to handle routine blood draws and imaging while the principal site manages protocol-specific procedures.

If you are weighing trials alongside non-trial options - international procedures, off-label regimens, or integrative protocols - a specialist can review the full clinical picture before you commit to any one path. You can consult the Art of Healing Cancer team on what your treatment options actually look like across both trial and non-trial pathways, remotely, before you decide.

When to Talk to Your Doctor

Raise the question of clinical trials at your first neuro-oncology appointment after diagnosis - before treatment begins, not after. Ask specifically whether the treating institution has open trials, what your molecular markers show, and whether your current performance status meets typical enrollment thresholds. If you are approaching recurrence, ask the same questions again. Eligibility changes as your clinical picture changes, and a trial that wasn't open at diagnosis may be available now.

If your care team doesn't have trials, or if you want a broader view of what is available beyond one institution, you can upload your MRI, pathology report, and treatment summary through Glioblastoma Center's patient journey form for a remote case review.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.